A single site study to investigate the current prevalence of anti-hepatitis C virus antibody among substance use disorder patients in Hiroshima-Insufficient testing and diagnosis.
HCV seroprevalence
harm reduction
hepatitis C virus
people who inject drugs
people who use drugs
Journal
Neuropsychopharmacology reports
ISSN: 2574-173X
Titre abrégé: Neuropsychopharmacol Rep
Pays: United States
ID NLM: 101719700
Informations de publication
Date de publication:
16 May 2023
16 May 2023
Historique:
revised:
26
04
2023
received:
03
02
2023
accepted:
26
04
2023
medline:
17
5
2023
pubmed:
17
5
2023
entrez:
16
5
2023
Statut:
aheadofprint
Résumé
Hepatitis C virus (HCV) infection among drug users presents an important public health problem; however, little recognition and few approaches to address this issue in Japan. This study was conducted to investigate the current disease status by assessing anti-HCV antibody (Ab) seroprevalence among people who inject drugs (PWIDs) and people who use drugs (PWUDs) in Hiroshima, Japan. This study was a psychiatric single-site chart review in patients with drug abuse problems in the Hiroshima region. The primary outcome was anti-HCV Ab prevalence among PWIDs who underwent anti-HCV Ab testing. The secondary outcomes included the prevalence of anti-HCV Ab among PWUDs who underwent anti-HCV Ab testing and the proportion of patients who underwent anti-HCV Ab examination. A total of 222 PWUD patients were enrolled. Among these, 16 patients (7.2%) had records of injection drug use (PWIDs). Eleven (68.8%) of the 16 PWIDs received anti-HCV Ab tests, and 4 (36.4%, 4/11) were anti-HCV Ab-positive. Among 222 PWUDs, 126 (56.8%) patients received anti-HCV Ab tests, and 57 of these patients (45.2%, 57/126) were anti-HCV Ab-positive. The prevalence of anti-HCV Ab among PWIDs and PWUDs who visited the study site was higher than the general population, which was 2.2% among hospitalized patients between May 2018 and November 2019. Considering the World Health Organization's (WHO) elimination goal and recent advances in HCV treatment, patients with drug abuse experience should be encouraged to take HCV tests and consult hepatologists for further investigations and treatment if they are positive for anti-HCV Ab.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : AbbVie GK, Japan
Informations de copyright
© 2023 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.
Références
World Health Organization [Internet]. Final global health sector strategies on respectively, HIV, viral hepatitis and sexually transmitted infections, 2022-2030. [cited 2022 Oct 20]. Available from: https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/strategies/global-health-sector-strategies/developing-ghss-2022-2030
European Association for Study of the Liver [Internet]. Policy statement on drug use and the global hepatitis C elimination goal. [cited 2022 Oct 20]. Available from: https://easl.eu/publication/policy-statement-drug-use-hepc/
American Association for the Study of Liver Diseases Infectious Diseases Society of America [Internet]. HCV guidance: Recommendations for testing, managing, and treating hepatitis C. [cited 2022 Oct 20]. Available from: https://www.hcvguidelines.org/unique-populations/key
Centers for Disease Control and Prevention [Internet]. Viral hepatitis. [cited 2022 Oct 20]. Available from: https://www.cdc.gov/hepatitis/index.htm
Tamori A, Uchida-Kobayashi S, Kozuka R, Motoyama H, Yoshida K, Odagiri N, et al. High dropout rate from aftercare program of antihepatitis C therapy for patients with history of injection drug use. JGH Open. 2020;4(5):964-9.
Tanaka J, Akita T, Ko K, Miura Y, Satake M. Countermeasures against viral hepatitis B and C in Japan: an epidemiological point of view. Hepatol Res. 2019;49(9):990-1002.
Ministry of Health Labour and Welfare [Internet]. The results of viral hepatitis testing from 2002 to 2006. (in Japanese). [cited 2022 Oct 20]. Available from: https://www.mhlw.go.jp/houdou/2007/10/h1003-1.html
Ministry of Health Labour and Welfare [Internet]. The 24th council for promotion of measures against hepatitis (in Japanese). [cited 2022 Oct 20]. Available from: https://www.mhlw.go.jp/stf/newpage_08387.html
Toyoda H, Atsukawa M, Uojima H, Nozaki A, Tamai H, Takaguchi K, et al. Trends and efficacy of interferon-free anti-hepatitis C virus therapy in the region of high prevalence of elderly patients, cirrhosis, and hepatocellular carcinoma: a real-world, nationwide, multicenter study of 10 688 patients in Japan. Open Forum Infect Dis. 2019;6(5):ofz185.
Nozaki A, Atsukawa M, Kondo C, Toyoda H, Chuma M, Nakamuta M, et al. The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study. Hepatol Int. 2020;14(2):225-38.
Wada K. “Research project on HIV infection and behavior monitoring among drug abusers and addicts”, Research program for counter measures of AIDS, Health and labor sciences research grant. (in Japanese). 2017.
Jafari S, Copes R, Baharlou S, Etminan M, Buxton J. Tattooing and the risk of transmission of hepatitis C: a systematic review and meta-analysis. Int J Infect Dis. 2010;14(11):e928-40.
Hiroshima Prefecture [Internet]. Press release about an agreement for promoting countermeasures against viral hepatitis between Hiroshima prefecture, Hiroshima University, and AbbVie. (in Japanese). [cited 2022 Oct 20]. Available from: https://www.pref.hiroshima.lg.jp/site/kanenshinsei/hepacontract.html
Toyoda H, Atsukawa M, Watanabe T, Nakamuta M, Uojima H, Nozaki A, et al. Marked heterogeneity in the diagnosis of compensated cirrhosis of patients with chronic hepatitis C virus infection in a real-world setting: a large, multicenter study from Japan. J Gastroenterol Hepatol. 2020;35(8):1420-5.
Yamamoto T, Kimura T, Tamakoshi A, Matsumoto T. Biennial changes in the characteristics of patients with methamphetamine use disorder in Japan from 2000 to 2020. J Psychoactive Drugs. 2022;1-9. doi:10.1080/02791072.2022.2105181. Online ahead of print.
Satake H. [Internet]. “Fact-finding survey on hepatitis C virus infection at medical institutions”, Health and labour sciences research grant, Research on hepatitis. (in Japanese). [cited 2022 Oct 20]. Available from: https://mhlw-grants.niph.go.jp/system/files/2019/192161/201921003A_upload/201921003A0005.pdf
Tanaka J, Sakamune K, Kurisu A, Akita T, Ohisa M, Sugiyama A. [Internet]. “Fact-finding survey on hepatitis examinations”, Health and labour sciences research grant, Research on hepatitis. (in Japanese). [cited 10 Mar 2023]. Available from: https://mhlw-grants.niph.go.jp/system/files/2017/172131/201720001A_upload/201720001A0027.pdf
Lens S, Miralpeix A, Gálvez M, Martró E, González N, Rodríguez-Tajes S, et al. HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates. JHEP Rep. 2022;4(12):100580.
Severe B, Tetrault JM, Madden L, Heimer R. Co-located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention. Drug Alcohol Depend. 2020;213:108116.
Tsui JI, Miller CM, Scott JD, Corcorran MA, Dombrowski JC, Glick SN. Hepatitis C continuum of care and utilization of healthcare and harm reduction services among persons who inject drugs in Seattle. Drug Alcohol Depend. 2019;195:114-20.
Kikuchi M, Matsutani N, Ishihara R, Sugihara M, Mizuno Y, Chiba C, et al. Inter-professional and inter-departmental alcoholism rehabilitation program. Clin Mol Hepatol. 2020;26(4):626-32.
Kawaguchi I, Chayama K, Gonzalez YS, Virabhak S, Mitchell D, Yuen C, et al. A cost-effectiveness analysis of glecaprevir/pibrentasvir versus existing direct-acting antivirals to treat chronic hepatitis C in Japan. Adv Ther. 2020;37(1):457-76.
Hajarizadeh B, Cunningham EB, Valerio H, Martinello M, Law M, Janjua NZ, et al. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: a meta-analysis. J Hepatol. 2020;72(4):643-57.
Grebely J, Dore GJ, Altice FL, Conway B, Litwin AH, Norton BL, et al. Reinfection and risk behaviors after treatment of hepatitis C virus infection in persons receiving opioid agonist therapy: a cohort study. Ann Intern Med. 2022;175(9):1221-9.
National Institute of Mental Health [Internet]. Research Report. (in Japanese). [cited 2023 Apr 20]. Available from: https://www.ncnp.go.jp/nimh/yakubutsu/report/index.html
Ministry of Health Labour and Welfare [Internet]. Promotion of control measures for hepatitis. (in Japanese). [cited 2022 Oct 20]. Available from: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/kenkou/kekkaku-kansenshou/kanen/index.html